RS57216B1 - Hemijske vrste - Google Patents
Hemijske vrsteInfo
- Publication number
- RS57216B1 RS57216B1 RS20180576A RSP20180576A RS57216B1 RS 57216 B1 RS57216 B1 RS 57216B1 RS 20180576 A RS20180576 A RS 20180576A RS P20180576 A RSP20180576 A RS P20180576A RS 57216 B1 RS57216 B1 RS 57216B1
- Authority
- RS
- Serbia
- Prior art keywords
- chemical entities
- entities
- chemical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13382089 | 2013-03-15 | ||
PCT/GB2014/050825 WO2014140644A1 (en) | 2013-03-15 | 2014-03-14 | Chemical entities |
EP14716910.6A EP2970332B1 (en) | 2013-03-15 | 2014-03-14 | Chemical entities |
Publications (1)
Publication Number | Publication Date |
---|---|
RS57216B1 true RS57216B1 (sr) | 2018-07-31 |
Family
ID=48013903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RS20180576A RS57216B1 (sr) | 2013-03-15 | 2014-03-14 | Hemijske vrste |
Country Status (32)
Country | Link |
---|---|
US (1) | US9453031B2 (sr) |
EP (1) | EP2970332B1 (sr) |
JP (1) | JP6379115B2 (sr) |
KR (1) | KR102206318B1 (sr) |
CN (1) | CN105051047B (sr) |
AR (1) | AR095443A1 (sr) |
AU (1) | AU2014229735B2 (sr) |
BR (1) | BR112015023060B1 (sr) |
CA (1) | CA2904768C (sr) |
CL (1) | CL2015002591A1 (sr) |
CY (1) | CY1120619T1 (sr) |
DK (1) | DK2970332T3 (sr) |
EA (1) | EA029771B1 (sr) |
ES (1) | ES2670674T3 (sr) |
HK (1) | HK1215021A1 (sr) |
HR (1) | HRP20180839T1 (sr) |
HU (1) | HUE037685T2 (sr) |
IL (1) | IL240708B (sr) |
LT (1) | LT2970332T (sr) |
MX (1) | MX368056B (sr) |
NO (1) | NO2970332T3 (sr) |
NZ (1) | NZ711038A (sr) |
PE (1) | PE20152007A1 (sr) |
PH (1) | PH12015502159B1 (sr) |
PL (1) | PL2970332T3 (sr) |
PT (1) | PT2970332T (sr) |
RS (1) | RS57216B1 (sr) |
SG (1) | SG11201507555PA (sr) |
SI (1) | SI2970332T1 (sr) |
TW (1) | TWI557131B (sr) |
UA (1) | UA118261C2 (sr) |
WO (1) | WO2014140644A1 (sr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9278950B2 (en) | 2013-01-14 | 2016-03-08 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
BR122019024759B1 (pt) | 2013-01-15 | 2022-02-08 | Incyte Holdings Corporation | Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos |
JP2016528298A (ja) | 2013-08-23 | 2016-09-15 | インサイト・コーポレイションIncyte Corporation | Pimキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物 |
WO2016010897A1 (en) | 2014-07-14 | 2016-01-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016112374A2 (en) * | 2015-01-09 | 2016-07-14 | The General Hospital Corporation | Treating cancer using inhibitors of ataxia-telangiectasia mutated and rad3-related (atr) |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
TWI734699B (zh) | 2015-09-09 | 2021-08-01 | 美商英塞特公司 | Pim激酶抑制劑之鹽 |
US9920032B2 (en) | 2015-10-02 | 2018-03-20 | Incyte Corporation | Heterocyclic compounds useful as pim kinase inhibitors |
EP3464295B1 (en) * | 2016-05-24 | 2020-02-05 | Merck Patent GmbH | Tricyclic heterocylic derivatives |
WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
JP7290651B2 (ja) | 2018-02-07 | 2023-06-13 | ウーシー・バイオシティ・バイオファーマシューティクス・カンパニー・リミテッド | Atr阻害剤及びその応用 |
WO2020094084A1 (zh) * | 2018-11-07 | 2020-05-14 | 南京明德新药研发有限公司 | 作为ret抑制剂的三并环衍生物 |
CN113004303A (zh) * | 2019-12-18 | 2021-06-22 | 江苏恒瑞医药股份有限公司 | 嘧啶并噁嗪类三环衍生物、其制备方法及其在医药上的应用 |
WO2021143821A1 (zh) * | 2020-01-17 | 2021-07-22 | 江苏恒瑞医药股份有限公司 | 稠合杂芳基类衍生物、其制备方法及其在医药上的应用 |
AU2021360636A1 (en) | 2020-10-16 | 2023-06-15 | Shanghai De Novo Pharmatech Co., Ltd. | Triheterocyclic derivative, and pharmaceutical composition and application thereof |
CN115466258A (zh) * | 2021-06-11 | 2022-12-13 | 成都苑东生物制药股份有限公司 | Atr抑制剂及其用途 |
CN115286645A (zh) * | 2022-08-16 | 2022-11-04 | 南京雷正医药科技有限公司 | 三环杂环衍生物及其药物组合物和用途 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5583024A (en) | 1985-12-02 | 1996-12-10 | The Regents Of The University Of California | Recombinant expression of Coleoptera luciferase |
AU3427093A (en) * | 1992-01-15 | 1993-08-03 | E.I. Du Pont De Nemours And Company | Bridged heterocyclic fungicides |
JPH08336393A (ja) | 1995-04-13 | 1996-12-24 | Mitsubishi Chem Corp | 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法 |
DE69837529T2 (de) | 1997-02-12 | 2007-07-26 | Electrophoretics Ltd., Cobham | Proteinmarker für lungenkrebs und deren verwendung |
GB9714249D0 (en) | 1997-07-08 | 1997-09-10 | Angiogene Pharm Ltd | Vascular damaging agents |
US6602677B1 (en) | 1997-09-19 | 2003-08-05 | Promega Corporation | Thermostable luciferases and methods of production |
GB9900334D0 (en) | 1999-01-07 | 1999-02-24 | Angiogene Pharm Ltd | Tricylic vascular damaging agents |
GB9900752D0 (en) | 1999-01-15 | 1999-03-03 | Angiogene Pharm Ltd | Benzimidazole vascular damaging agents |
EP1154774B1 (en) | 1999-02-10 | 2005-06-22 | AstraZeneca AB | Quinazoline derivatives as angiogenesis inhibitors |
SK287401B6 (sk) | 1999-11-05 | 2010-09-07 | Astrazeneca Ab | Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie |
NZ520640A (en) | 2000-02-15 | 2005-04-29 | Upjohn Co | Pyrrole substituted 2-indolinone protein kinase inhibitors |
EP1289952A1 (en) | 2000-05-31 | 2003-03-12 | AstraZeneca AB | Indole derivatives with vascular damaging activity |
UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
SK52003A3 (en) | 2000-07-07 | 2003-07-01 | Angiogene Pharm Ltd | Colchinol derivatives as angiogenesis inhibitors, method for their preparation and pharmaceutical composition comprising the same |
AU6623301A (en) | 2000-07-07 | 2002-01-21 | Angiogene Pharm Ltd | Colchinol derivatives as vascular damaging agents |
US8735411B2 (en) * | 2006-10-02 | 2014-05-27 | Abbvie Inc. | Macrocyclic benzofused pyrimidine derivatives |
CA2667960A1 (en) * | 2006-10-30 | 2008-05-08 | Novartis Ag | Imidazopyridazines as pi3k lipid kinase inhibitors |
EP2155753A1 (en) * | 2007-05-09 | 2010-02-24 | Novartis Ag | Substituted imidazopyridazines as pi3k lipid kinase inhibitors |
BR112012003955A2 (pt) * | 2009-08-20 | 2017-09-26 | Karus Therapeutics Ltd | compostos heterocíclicos tricíclicos como inibidores da fosfoinositídeos 3-quinase |
CN102020657A (zh) * | 2009-09-11 | 2011-04-20 | 上海艾力斯医药科技有限公司 | 稠合杂芳基衍生物、制备方法及其应用 |
AU2011270807A1 (en) * | 2010-06-23 | 2013-01-31 | Vertex Pharmaceuticals Incorporated | Pyrrolo- pyrazine derivatives useful as inhibitors of ATR kinase |
UA109688C2 (xx) * | 2010-12-16 | 2015-09-25 | Трициклічні інгібітори pі3k та їх застосування |
-
2014
- 2014-03-13 AR ARP140100990A patent/AR095443A1/es unknown
- 2014-03-14 HU HUE14716910A patent/HUE037685T2/hu unknown
- 2014-03-14 KR KR1020157025265A patent/KR102206318B1/ko active IP Right Grant
- 2014-03-14 JP JP2015562337A patent/JP6379115B2/ja active Active
- 2014-03-14 PT PT147169106T patent/PT2970332T/pt unknown
- 2014-03-14 PE PE2015001900A patent/PE20152007A1/es active IP Right Grant
- 2014-03-14 MX MX2015011549A patent/MX368056B/es active IP Right Grant
- 2014-03-14 CN CN201480015613.0A patent/CN105051047B/zh active Active
- 2014-03-14 CA CA2904768A patent/CA2904768C/en active Active
- 2014-03-14 TW TW103109396A patent/TWI557131B/zh active
- 2014-03-14 SG SG11201507555PA patent/SG11201507555PA/en unknown
- 2014-03-14 BR BR112015023060-1A patent/BR112015023060B1/pt active IP Right Grant
- 2014-03-14 LT LTEP14716910.6T patent/LT2970332T/lt unknown
- 2014-03-14 SI SI201430698T patent/SI2970332T1/en unknown
- 2014-03-14 EA EA201591781A patent/EA029771B1/ru not_active IP Right Cessation
- 2014-03-14 NZ NZ711038A patent/NZ711038A/en unknown
- 2014-03-14 ES ES14716910.6T patent/ES2670674T3/es active Active
- 2014-03-14 PL PL14716910T patent/PL2970332T3/pl unknown
- 2014-03-14 DK DK14716910.6T patent/DK2970332T3/en active
- 2014-03-14 WO PCT/GB2014/050825 patent/WO2014140644A1/en active Application Filing
- 2014-03-14 AU AU2014229735A patent/AU2014229735B2/en active Active
- 2014-03-14 EP EP14716910.6A patent/EP2970332B1/en active Active
- 2014-03-14 NO NO14716910A patent/NO2970332T3/no unknown
- 2014-03-14 UA UAA201510054A patent/UA118261C2/uk unknown
- 2014-03-14 RS RS20180576A patent/RS57216B1/sr unknown
- 2014-03-14 US US14/774,294 patent/US9453031B2/en active Active
-
2015
- 2015-08-20 IL IL240708A patent/IL240708B/en active IP Right Grant
- 2015-09-10 CL CL2015002591A patent/CL2015002591A1/es unknown
- 2015-09-15 PH PH12015502159A patent/PH12015502159B1/en unknown
-
2016
- 2016-03-14 HK HK16102921.2A patent/HK1215021A1/zh unknown
-
2018
- 2018-05-24 CY CY181100555T patent/CY1120619T1/el unknown
- 2018-05-25 HR HRP20180839TT patent/HRP20180839T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20180839T1 (hr) | Kemijske vrste | |
HK1222859A1 (zh) | 化合物 | |
AU355447S (en) | Case | |
AU354443S (en) | Case | |
AU354395S (en) | Case | |
AP2015008713A0 (en) | Tetrahydropyrrolothiazine compounds | |
GB201302927D0 (en) | Compounds | |
GB201304245D0 (en) | Chemical compounds | |
HK1214592A1 (zh) | 化合物 | |
GB201316824D0 (en) | New Chemical Entities | |
HK1215049A1 (zh) | 化學交聯劑 | |
AP3850A (en) | Azetidinyloxyphenylpyrrolidine compounds | |
GB201316823D0 (en) | New Chemical Entities | |
EP3010923A4 (en) | PYRROLOCHINAZOLINVERBINDUNGEN | |
EP2948457A4 (en) | COMPOUNDS | |
GB201322733D0 (en) | Chemical compounds | |
GB201306794D0 (en) | Compounds | |
GB201313885D0 (en) | Chemical Compounds | |
GB201306881D0 (en) | Chemical compounds | |
GB201317911D0 (en) | E e e | |
GB201304305D0 (en) | E C Trackograph | |
GB201307093D0 (en) | Compounds | |
GB201304694D0 (en) | Compounds | |
GB201303482D0 (en) | Compounds | |
GB201303483D0 (en) | Compounds |